A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
This study seeks to determine whether the addition of ABT-414 to concomitant radiation therapy
and temozolomide (TMZ) prolongs progression free survival (PFS) and overall survival (OS) in
participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor
In addition, there is a Phase 1, open-label, multicentre sub-study to assess the
pharmacokinetics, safety and tolerability of ABT-414 in subjects with newly diagnosed
EGFR-amplified GBM who have mild or moderate hepatic impairment.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society